Duboux Stéphane, Van Wijchen Myrthe, Kleerebezem Michiel
Nestlé Research, Lausanne, Switzerland.
Host-Microbe Interactomics Group, Wageningen University and Research, Wageningen, Netherlands.
Front Microbiol. 2021 Dec 24;12:812536. doi: 10.3389/fmicb.2021.812536. eCollection 2021.
Probiotics for food or supplement use have been studied in numerous clinical trials, addressing a broad variety of diseases, and conditions. However, discrepancies were observed in the clinical outcomes stemming from the use of lactobacillaceae and bifidobacteria strains. These differences are often attributed to variations in the clinical trial protocol like trial design, included target population, probiotic dosage, or outcome parameters measured. However, a contribution of the methods used to produce the live bioactive ingredients should not be neglected as a possible additional factor in the observed clinical outcome variations. It is well established that manufacturing conditions play a role in determining the survival and viability of probiotics, but much less is known about their influence on the probiotic molecular composition and functionality. In this review, we briefly summarize the evidence obtained for GG and WCFS1, highlighting that expression and presence of probiotic niche factor (NF) and/or effector molecules (EM) may be altered during production of those two well-characterized lactobacillaceae probiotic strains. Subsequently, we summarize in more depth what is the present state of knowledge about bifidobacterial probiotic NF and EM; how their expression may be modified by manufacturing related environmental factors and how that may affect their biological activity in the host. This review highlights the importance of gathering knowledge on probiotic NF and EM, to validate them as surrogate markers of probiotic functionality. We further propose that monitoring of validated NF and/or EM during production and/or in the final preparation could complement viable count assessments that are currently applied in industry. Overall, we suggest that implementation of molecular level quality controls (i.e., based on validated NF and EM), could provide mode of action based tests contributing to better control the health-promoting reliability of probiotic products.
用于食品或补充剂的益生菌已在众多临床试验中得到研究,涉及多种疾病和病症。然而,在使用乳酸杆菌科和双歧杆菌菌株的临床结果中观察到了差异。这些差异通常归因于临床试验方案的变化,如试验设计、纳入的目标人群、益生菌剂量或测量的结果参数。然而,用于生产活生物活性成分的方法的作用不应被忽视,它可能是观察到的临床结果差异的一个额外因素。众所周知,生产条件在决定益生菌的存活和活力方面发挥着作用,但关于它们对益生菌分子组成和功能的影响却知之甚少。在本综述中,我们简要总结了针对GG和WCFS1获得的证据,强调在这两种特征明确的乳酸杆菌科益生菌菌株的生产过程中,益生菌生态位因子(NF)和/或效应分子(EM)的表达和存在可能会发生改变。随后,我们更深入地总结了关于双歧杆菌益生菌NF和EM的现有知识状态;它们的表达如何受到与生产相关的环境因素的影响,以及这可能如何影响它们在宿主中的生物活性。本综述强调了收集关于益生菌NF和EM的知识的重要性,以验证它们作为益生菌功能的替代标志物。我们进一步建议,在生产过程中和/或最终制剂中监测经过验证的NF和/或EM可以补充目前工业中应用的活菌计数评估。总体而言,我们建议实施分子水平的质量控制(即基于经过验证的NF和EM),可以提供基于作用模式的测试,有助于更好地控制益生菌产品促进健康的可靠性。